



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Wolfgang Daum		Examiner:	Not Yet Known
Application No.:	10/078,622		Group Art Unit:	3738
Filing Date:	February 19, 2002			
Title:	STENT AND METHOD FOR DRUG DELIVERY FROM STENTS			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

I hereby certify that this document is being sent via First Class U. S. mail addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 21 day of June, 2002.


KrisAnne Popovits #3

Dear Sir:


Pursuant to 37 CFR 1.97(b), the references listed on the attached Form PTO-1449 (1 sheet, submitted in duplicate) are brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the identified references are enclosed as necessary.

This Supplemental IDS is being filed before the mailing of a first office action on the merits. In accordance with 37 CFR 1.97(b), no statement or fee is required.

Pursuant to the Manual of Patent Examining Procedure, Chapter 609, applicant requests that the Examiner consider each of the listed documents and initial and return to the undersigned a copy of the enclosed Form PTO-1449.

Respectfully submitted,
DORSEY & WHITNEY LLP

Date: June 21, 2002

By: 
Min (Amy) S. Xu
Reg. No. 39,536
Suite 1500
50 South Sixth Street
Minneapolis, Minnesota 55402-1498
Telephone: 612-752-7367

OIP INFORMATION STATEMENT
(use only)
JUN 27 2002

[illegible]

Examiner Initial		Document Number	Date	Country	Class	Sub-class	Translation
							No
							No

Examiner Initial	Document Description
	<u>Pilot Study Results of Cordis Sirolimus-Coated Bx VELOCITY™ Stent Reveal 'No Restenosis' in 45 Patients in Two Global Regions.</u> http://www.jnj.com/news_finanace/271.htm ; December 21, 2000.
	Keelan PC, Miyauchi K, Caplice NM, Ashai KH, Schwartz RS. <u>Modifications of molecular events in coronary restenosis using coated stents: The Mayo Clinic Approach.</u> Semin Intervent Cardiol 1998 Sept-Dec; 3: 211-215.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.